Calidi Biotherapeutics, Inc.
CLDI
$0.415
-$0.016-3.71%
AMEX
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 24.21% | 8.59% | 27.53% | -24.14% | -14.90% |
| Total Depreciation and Amortization | 22.21% | 53.52% | 107.53% | 270.08% | 383.08% |
| Total Amortization of Deferred Charges | -89.58% | -128.67% | -107.27% | -23.77% | 251.22% |
| Total Other Non-Cash Items | -62.18% | -81.39% | -114.50% | -46.05% | -17.84% |
| Change in Net Operating Assets | 72.80% | 137.11% | -1,299.43% | -3,936.28% | -274.89% |
| Cash from Operations | 27.01% | 24.21% | -70.58% | -94.91% | -104.20% |
| Capital Expenditure | 97.26% | 88.02% | 78.09% | 2.79% | -36.68% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -100.00% | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -44.44% | 1,266.67% | 248.48% | 248.48% |
| Cash from Investing | 96.65% | 92.38% | 84.72% | 34.96% | 3.24% |
| Total Debt Issued | 16.92% | -20.00% | -32.63% | 6.49% | 116.67% |
| Total Debt Repaid | 19.95% | -5,375.00% | -6,108.96% | -2,186.41% | -1,875.63% |
| Issuance of Common Stock | 8,038.79% | 3,189.32% | 2,306.06% | -44.75% | 146.49% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -100.00% | 275.67% | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -23.46% | -64.78% | -66.81% | -82.85% | -68.21% |
| Cash from Financing | -5.78% | -68.89% | 41.97% | 86.62% | 140.29% |
| Foreign Exchange rate Adjustments | -116.67% | -328.57% | 140.00% | 155.00% | 76.92% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 384.59% | -181.97% | -167.84% | -40.90% | 195.75% |